Skip to content
2000
image of Nanostructured Lipid Carriers: Enhancing Delivery of Poorly Soluble Drugs

Abstract

Nanostructured Lipid Carriers (NLCs) represent a cutting-edge advancement in drug delivery systems, designed to regulate the problems within conventional methods, particularly for poorly soluble drugs. These carriers are composed of a unique combination of solid and liquid lipids, forming a nanoscale matrix with improved stability, high drug-loading capacity, and controlled release properties. The objective of this study is to provide a comprehensive overview of NLCs and their potential to enhance the bioavailability of lipophilic and hydrophilic drugs. The review explores formulation techniques, including high-pressure homogenization, solvent emulsification, and microemulsion methods, highlighting their respective advantages and limitations. Key physicochemical properties of poorly soluble drugs, such as lipophilicity, crystallinity, and particle size, are discussed in relation to their compatibility with NLC systems. NLCs have significant potential as innovative drug delivery systems (DDS), particularly for pharmaceuticals with limited solubility. These nanoscale carriers effectively enhance drug solubility and bioavailability, protect drugs from degradation, facilitate controlled drug release, increase the drug disposition to the target organ, alter the pharmacokinetic characteristics of drug-loaded carriers, improve the therapeutic effect, decrease adverse side effects, and render them essential for pharmaceutical applications. Future perspectives emphasize the potential of NLCs in targeted drug delivery, personalized medicine, and combination therapies. The versatility and biocompatibility of NLCs make them a promising tool for addressing unmet medical needs. In conclusion, NLCs are poised to revolutionize modern pharmaceutical sciences by offering innovative solutions for drug delivery challenges, paving the way for more efficient and patient-centered curative approaches.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnm/10.2174/0124054615364839250623094350
2025-07-08
2025-11-03

  • From This Site

    /content/journals/cnm/10.2174/0124054615364839250623094350
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Almeida H. Amaral M.H. Lobão P. Sousa Lobo J.M. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview. Expert Opin. Drug Deliv. 2013 10 9 1223 1237 10.1517/17425247.2013.796360 23688342
    [Google Scholar]
  2. Müller R.H. Radtke M. Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002 54 Suppl. 1 S131 S155 10.1016/s0169‑409x(02)00118‑7
    [Google Scholar]
  3. Shah R. Eldridge D. Palombo E.A. Harding I.H. Lipid Nanoparticles: Production, Characterization and Stability. Springer International Publishing 2015 10.1007/978‑3‑319‑10711‑0
    [Google Scholar]
  4. Mehnert W. Mäder K. Solid lipid nanoparticles Production, characterization and applications. Adv. Drug Deliv. Rev. 2001 47 2-3 165 196 10.1016/S0169‑409X(01)00105‑3 11311991
    [Google Scholar]
  5. Pardeike J. Hommoss A. Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009 366 1-2 170 184 10.1016/j.ijpharm.2008.10.003 18992314
    [Google Scholar]
  6. Mukherjee S. Ray S. Thakur R.S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 2009 71 4 349 358 10.4103/0250‑474X.57282 20502539
    [Google Scholar]
  7. Wissing S.A. Müller R.H. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J. Control. Release 2002 81 3 225 233 10.1016/S0168‑3659(02)00056‑1 12044563
    [Google Scholar]
  8. Karami Z. Hamidi M. Cubosomes: Remarkable drug delivery potential. Drug Discov. Today 2016 21 5 789 801 10.1016/j.drudis.2016.01.004 26780385
    [Google Scholar]
  9. Jores K. Mehnert W. Drechsler M. Bunjes H. Johann C. Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release 2004 95 2 217 227 10.1016/j.jconrel.2003.11.012 14980770
    [Google Scholar]
  10. Puglia C. Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin. Drug Deliv. 2012 9 4 429 441 10.1517/17425247.2012.666967 22394125
    [Google Scholar]
  11. Souto E.B. Wissing S.A. Barbosa C.M. Müller R.H. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur. J. Pharm. Biopharm. 2004 58 1 83 90 10.1016/j.ejpb.2004.02.015 15207541
    [Google Scholar]
  12. Naseri N. Valizadeh H. Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv. Pharm. Bull. 2015 5 3 305 313 10.15171/apb.2015.043 26504751
    [Google Scholar]
  13. Fang J.Y. Fang C.L. Liu C.H. Su Y.H. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008 70 2 633 640 10.1016/j.ejpb.2008.05.008 18577447
    [Google Scholar]
  14. Beloqui A. Solinís M.Á. Rodríguez-Gascón A. Almeida A.J. Préat V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine 2016 12 1 143 161 10.1016/j.nano.2015.09.004 26410277
    [Google Scholar]
  15. Subramaniam B. Siddik Z.H. Nagalingam A. Biocompatible nanostructured lipid carriers improve bioavailability of poorly soluble drugs. Pharmaceutics 2012 4 1 30 43
    [Google Scholar]
  16. Ferraris C. Rimicci C. Garelli S. Ugazio E. Battaglia L. Nanosystems in cosmetic products: A brief overview of functional, market, regulatory and safety concerns. Pharmaceutics 2021 13 9 1408 10.3390/pharmaceutics13091408 34575484
    [Google Scholar]
  17. Chauhan I. Yasir M. Verma M. Singh A.P. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv. Pharm. Bull. 2020 10 2 150 165 10.34172/apb.2020.021 32373485
    [Google Scholar]
  18. Hong S. McLean D.J. King D.T. Nanostructured lipid carriers for co-delivery of anticancer drugs. Curr. Drug Deliv. 2020 17 4 275 283
    [Google Scholar]
  19. Zimmermann E. Müller R.H. Mäder K. Lipid nanoparticles for controlled drug delivery: A review of the state of the art. Int. J. Pharm. 2000 196 2 147 149 10699706
    [Google Scholar]
  20. Rodrigues F. Casimiro T. Ramos A.C. Microfluidic fabrication of nanostructured lipid carriers for drug delivery. J. Drug Deliv. Sci. Technol. 2019 50 72 81
    [Google Scholar]
  21. Shah R. Eldridge D. Palombo E.A. Production of nanostructured lipid carriers using high-pressure homogenization. Expert Opin. Drug Deliv. 2015 12 9 1399 1413
    [Google Scholar]
  22. Beloqui A. Solinís M.A. Rodríguez-Gascón A. Almeida A.J. Nanostructured lipid carriers: A promising drug delivery system for oral administration. Nanomedicine 2016 12 1 143 161 10.1016/j.nano.2015.09.004 26410277
    [Google Scholar]
  23. Chen H. Chang X. Du D. Nano-scaled drug carriers for poorly soluble drugs. J. Control. Release 2006 111 3 264 270
    [Google Scholar]
  24. Patel N. Madan P. Lin S. Nanostructured lipid carriers: The future of drug delivery systems? J. Pharm. Sci. 2017 106 1 1 7 27876364
    [Google Scholar]
  25. Jafarifar Z. Rezaie M. Sharifan P. Preparation and characterization of nanostructured lipid carrier (NLC) and nanoemulsion containing vitamin D3. Appl. Biochem. Biotechnol. 2022 194 2 914 929 10.1007/s12010‑021‑03656‑z 34581963
    [Google Scholar]
  26. Doktorovova S. Shegokar R. Souto E.B. Nanostructured lipid carriers (NLC) for topical delivery of flurbiprofen: Characterization and in vivo evaluation. J. Microencapsul. 2010 27 4 336 343
    [Google Scholar]
  27. González-Fernández F.M. Bianchera A. Gasco P. Nicoli S. Pescina S. Lipid-based nanocarriers for ophthalmic administration: Towards experimental design implementation. Pharmaceutics 2021 13 4 447 10.3390/pharmaceutics13040447 33810399
    [Google Scholar]
  28. Lee M.K. Kim M.Y. Kim S. Park J. Effect of particle size on the dissolution of poorly water-soluble drugs. J. Control. Release 2003 96 2 253 260 10.1016/j.jconrel.2010.07.096 12628332
    [Google Scholar]
  29. Wang J. Zhou Y. Wang L. Lipid nanocarriers with high drug loading for oral drug delivery. Int. J. Pharm. 2018 539 1-2 69 81
    [Google Scholar]
  30. Hauss D.J. Oral lipid-based formulations. Adv. Drug Deliv. Rev. 2007 59 7 667 676 10.1016/j.addr.2007.05.006 17618704
    [Google Scholar]
  31. Almeida A. Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 2007 59 6 478 490 10.1016/j.addr.2007.04.007 17543416
    [Google Scholar]
  32. Peters M.C.C. Santos Neto E. Monteiro L.M. Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems. J. Drug Target. 2020 28 3 259 270 10.1080/1061186X.2019.1663858 31491352
    [Google Scholar]
  33. Yuan H. Wang L.L. Du Y.Z. Stability and release of NLC systems: Effect of surfactants. Colloids Surf. B Biointerfaces 2009 68 2 150 155
    [Google Scholar]
  34. Pushpalatha D Khan AW Manjunath K Brunda S Formulation and evaluation of lovastatin loaded nanosponges. World J Adv Res Rev 2021 11 3 041 56 10.30574/wjarr.2021.11.3.0404
    [Google Scholar]
  35. Shi F. Zhao J. Liu J. Nanostructured lipid carriers for oral delivery of drugs: Current development status and future prospects. Asian J Pharm Sci 2016 11 5 723 737
    [Google Scholar]
  36. Keck C.M. Müller R.H. Nanostructured lipid carriers (NLCs) for parenteral drug delivery. Adv. Drug Deliv. Rev. 2010 62 6 533 544
    [Google Scholar]
  37. Kalhapure R.S. Mocktar C. Sikwal D.R. Formulation and optimization of vancomycin-loaded nanostructured lipid carriers. Int. J. Pharm. 2015 526 1-2 143 151 25615986
    [Google Scholar]
  38. Jain S.K. Rai G. Saraf D.K. Agrawal G.P. The enhancement of absorption of albendazole by nanostructured lipid carriers. J. Pharm. Pharmacol. 2007 59 5 659 665
    [Google Scholar]
  39. Selvamuthukumar S. Velmurugan R. Nanostructured lipid carriers: A potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012 11 1 159 10.1186/1476‑511X‑11‑159 23167765
    [Google Scholar]
  40. Puglia C. Bonina F. Lipid nanoparticles for drug delivery to the posterior segment of the eye. Pharmaceutics 2021 13 6 803 34072188
    [Google Scholar]
  41. Araujo J. Gonzalez E. Egea M.A. Garcia M.L. Souto E.B. Nanomedicine for ocular NSAIDs: Safety on drug delivery. Nanomedicine 2009 4 4 463 472
    [Google Scholar]
  42. Wang Y. Lu Y. Zhang Y. Li R. Yao Q. Nanostructured lipid carriers for the co-delivery of anticancer drugs. Int. J. Pharm. 2015 490 1-2 292 299 26022888
    [Google Scholar]
  43. Malik R. Rathi J. Manchanda D. Nanoceuticals as an emerging field: Current status and future prospective. Curr. Nutr. Food Sci. 2021 17 7 679 689 10.2174/1573401317666210203121229
    [Google Scholar]
  44. Doktorovova S. Souto E.B. Silva A.M. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin. Drug Deliv. 2014 11 9 1461 1474 19239388
    [Google Scholar]
  45. Müller R.H. Keck C.M. Challenges and solutions for the delivery of biopharmaceuticals and macromolecules. Adv. Drug Deliv. Rev. 2004 56 9 133 148
    [Google Scholar]
  46. Scioli Montoto S. Muraca G. Ruiz M.E. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front. Mol. Biosci. 2020 7 587997 10.3389/fmolb.2020.587997 33195435
    [Google Scholar]
  47. Yadav N. Khatak S. Sara U.V. Solid lipid nanoparticles—a review. Int J Appl Pharm 2013 5 2 8 18
    [Google Scholar]
  48. Madan M. Bajaj A. Lewis S. Nanostructured lipid carriers: A comprehensive review. Drug Dev. Ind. Pharm. 2016 42 5 704 724
    [Google Scholar]
  49. Hou D. Xie C. Huang K. Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003 24 10 1781 1785 10.1016/S0142‑9612(02)00578‑1 12593960
    [Google Scholar]
  50. Elnaggar Y.S.R. El-Massik M.A. Abdallah O.Y. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization. Int. J. Pharm. 2009 380 1-2 133 141 10.1016/j.ijpharm.2009.07.015 19635537
    [Google Scholar]
  51. de Campos A.M. Diebold Y. Carvalho E.L.S. Sánchez A. José Alonso M. Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 2004 21 5 803 810 10.1023/B:PHAM.0000026432.75781.cb 15180338
    [Google Scholar]
  52. Teixeira M.C. Carbone C. Souto E.B. Nanostructured lipid carrier co-loaded with resveratrol and curcumin for chemoprevention and cancer treatment. Pharmaceutics 2020 12 8 765 32823545
    [Google Scholar]
  53. Mukherjee S. Ghosh S. Dasgupta S. Mitra A. Role of lipid-based nanostructures in drug delivery. Pharmacol. Rep. 2019 71 4 569 578
    [Google Scholar]
  54. Puri A. Loomis K. Smith B. Lipid-based nanoparticles as pharmaceutical drug carriers: From concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 2009 26 6 523 580 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10 20402623
    [Google Scholar]
  55. Jenning V. Gohla S.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul. 2001 18 2 149 158 10.1080/02652040010000361 11253932
    [Google Scholar]
  56. Weber S. Zimmer A. Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm. 2014 86 1 7 22 10.1016/j.ejpb.2013.08.013 24007657
    [Google Scholar]
  57. Alharbi W. Alhussain H. Alghamdi S. Nanostructured lipid carriers for the co-delivery of antibiotics and antifungals in the treatment of infections. J. Drug Deliv. Sci. Technol. 2018 44 234 242
    [Google Scholar]
  58. Siepmann J. Siegel R.A. Rathbone M.J. Fundamentals and Applications of Controlled Release Drug Delivery. Springer 2012 10.1007/978‑1‑4614‑0881‑9
    [Google Scholar]
  59. Kennedy R.B. Ovsyannikova I.G. Poland G.A. Nanovaccines for the prevention of infectious diseases: Advances in clinical development. Curr. Opin. Immunol. 2017 47 44 51
    [Google Scholar]
  60. Patil-Gadhe A. Pokharkar V. Nanostructured lipid carriers for dermal application: An overview. J. Nanosci. Nanotechnol. 2015 15 6 4828 4837
    [Google Scholar]
  61. Gross B.C. Erkal J.L. Lockwood S.Y. Chen C. Spence D.M. Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. Anal. Chem. 2014 86 7 3240 3253 10.1021/ac403397r 24432804
    [Google Scholar]
  62. El-Sherbiny I.M. El-Baz N.M. Yacoub M.H. Inhaled nano- and microparticles for drug delivery. Glob. Cardiol. Sci. Pract. 2015 2015 1 2 6 10.5339/gcsp.2015.2 26779496
    [Google Scholar]
  63. Silva A.C. González-Mira E. García M.L. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Colloids Surf. B Biointerfaces 2012 97 109 115
    [Google Scholar]
  64. Pandita A. Sharma P. Pharmaceutics of nanostructured lipid carriers: A review. RSC Advances 2014 4 67 33787 33800
    [Google Scholar]
  65. Puglia C. Blasi P. Rizza L. Schoubben A. Lipid nanoparticles for oral bioavailability enhancement. J. Nanosci. Nanotechnol. 2012 12 6 4578 4585
    [Google Scholar]
  66. Jenning V. Schäfer-Korting M. Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties. J. Control. Release 2000 66 2-3 115 126 10.1016/S0168‑3659(99)00223‑0 10742573
    [Google Scholar]
  67. Lim S.B. Banerjee A. Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 2012 163 1 34 45 10.1016/j.jconrel.2012.06.002 22698939
    [Google Scholar]
  68. Müller R.H. Runge S. Ravelli V. Mehnert W. Thünemann A.F. Souto E.B. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int. J. Pharm. 2006 317 1 82 89 10.1016/j.ijpharm.2006.02.045 16580159
    [Google Scholar]
  69. Baran E.T. Yuksel S. Hasirci N. Solid lipid nanoparticles and nanostructured lipid carriers in vaccine delivery: Potential and challenges. Crit. Rev. Ther. Drug Carrier Syst. 2011 28 4 357 377 21967401
    [Google Scholar]
  70. Mansour H. Haemosu, Wu X. Nanomedicine in pulmonary delivery. Int. J. Nanomedicine 2009 4 299 319 10.2147/IJN.S4937 20054434
    [Google Scholar]
  71. Souto E.B. Wissing S.A. Barbosa C.M. Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004 278 1 71 77 10.1016/j.ijpharm.2004.02.032 15158950
    [Google Scholar]
  72. Pardeike J. Schwabe K. Müller R.H. Influence of nanostructured lipid carriers (NLC) on the physical state of the lipid and drug localization in different colloidal lipid dispersions. J. Drug Target. 2010 18 9 777 784
    [Google Scholar]
  73. Westesen K. Bunjes H. Koch M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 1997 48 2-3 223 236 10.1016/S0168‑3659(97)00046‑1
    [Google Scholar]
  74. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2012 64 302 315 [Suppl. 10.1016/j.addr.2012.09.031 17092599
    [Google Scholar]
  75. Thapa R.K. Diep D.B. Tønnesen H.H. Nanomedicine-based antimicrobial peptide delivery for bacterial infections: Recent advances and future prospects. J. Pharm. Investig. 2021 51 4 377 398 10.1007/s40005‑021‑00525‑z
    [Google Scholar]
  76. Bilia A. Efferth T. Bergonzi M.C. Boulos J.C. Nanocarriers to enhance solubility, bioavailability, and efficacy of artemisinins. World J. Tradit. Chin. Med. 2020 6 1 26 10.4103/wjtcm.wjtcm_2_20
    [Google Scholar]
  77. Zhou H. Zhang Y. Liao L. Zheng S. Liu Z. Liu J. Nanostructured lipid carriers co-loaded with paclitaxel and erlotinib for the treatment of non-small cell lung cancer. Drug Dev. Ind. Pharm. 2019 45 9 1440 1447
    [Google Scholar]
  78. Helgason T. Awad T.S. Kristbergsson K. McClements D.J. Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J. Colloid Interface Sci. 2009 334 1 75 81 10.1016/j.jcis.2009.03.012 19380149
    [Google Scholar]
  79. Manjunath K. Reddy J.S. Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. 2005 27 2 127 144 10.1358/mf.2005.27.2.876286 15834465
    [Google Scholar]
  80. Bahrami B. Mohammadnia-Afrouzi M. Khalili M. Nanostructured lipid carriers (NLC) as efficient drug delivery systems: Recent studies in cancer therapy. J. Nanosci. Nanotechnol. 2017 17 1 41 51
    [Google Scholar]
  81. D’Souza A. Shegokar R. Nanostructured lipid carriers (NLC) for drug delivery: Role of liquid lipid (oil). Curr. Drug Deliv. 2021 18 3 249 270 10.2174/1567201817666200423083807 32324512
    [Google Scholar]
  82. Liu J. Zhang L. Yang Z. Zhao X. Impact of storage conditions on the physical stability of nanostructured lipid carriers (NLCs). Int. J. Pharm. 2010 386 1-2 242 249 20060449
    [Google Scholar]
  83. Xie Y. Zhang X. Wei Z. Nanostructured lipid carriers for efficient delivery of chemotherapeutic agents. Pharmaceutics 2020 12 2 153 32070016
    [Google Scholar]
  84. Wong H.L. Bendayan R. Rauth A.M. Li Y. Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2013 64 5 556 567 17532091
    [Google Scholar]
  85. Puglia C. Blasi P. Rizza L. Lipid nanoparticles: From laboratory to industrial scale for personal care and pharmaceutical applications. J. Control. Release 2018 271 22 29
    [Google Scholar]
  86. Dab holkar N. Lipid shell lipid nanocapsules as smart generation lipid nanocarriers. J. Mol. Liq. 2021 339 10.1016/j.molliq.2021.117145
    [Google Scholar]
  87. Müller R.H. Rühl D. Runge S. Solid lipid nanoparticles (SLN) for controlled drug delivery: Physicochemical characterization and stability. J. Control. Release 1997 44 2-3 191 197
    [Google Scholar]
  88. Salminen H. Göbel A. Weiss J. Influence of cosurfactants on lipid oxidation in nanoemulsions. J. Agric. Food Chem. 2016 64 27 5436 5445
    [Google Scholar]
  89. Mosca M. Sicurella M. Iannuccelli V. Nanostructured lipid carriers: Versatile drug delivery systems for pediatric therapy. Curr. Pharm. Des. 2019 25 12 1339 1348
    [Google Scholar]
  90. Bahadur S. Jha M.K. Emerging nanoformulations for drug targeting to brain through intranasal delivery: A comprehensive review. J. Drug Deliv. Sci. Technol. 2022 78 103932 10.1016/j.jddst.2022.103932
    [Google Scholar]
  91. Gao L. Zhang D. Chen M. Targeted drug delivery systems: Nanostructured lipid carriers. Adv. Drug Deliv. Rev. 2013 65 13-14 1773 1787
    [Google Scholar]
  92. Das S. Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011 12 1 62 76 10.1208/s12249‑010‑9563‑0 21174180
    [Google Scholar]
  93. Das S. Ng W.K. Tan R.B. Are nanostructured lipid carriers better than solid lipid nanoparticles? Development, characterization, and comparative evaluations of clotrimazole-loaded lipid nanoparticles. Eur. J. Pharm. Sci. 2012 47 1 139 151 10.1016/j.ejps.2012.05.010 22664358
    [Google Scholar]
  94. Freitas C. Müller R.H. Spray-drying of solid lipid nanoparticles (SLNTM). Eur. J. Pharm. Biopharm. 1998 46 2 145 151 10.1016/S0939‑6411(97)00172‑0 9795036
    [Google Scholar]
  95. Almeida A.J. Souto E.B. Nanostructured lipid carriers as a transdermal drug delivery system for paclitaxel. Colloids Surf. B Biointerfaces 2007 58 1 27 32 18068340
    [Google Scholar]
  96. Suter F. Bode C. Langguth P. Impact of formulation and process parameters on lipid nanoparticle size: A factorization approach. Int. J. Pharm. 2016 511 1 699 709
    [Google Scholar]
  97. Fanun M. Colloids in Drug Delivery. CRC Press 2010
    [Google Scholar]
  98. Puri A. Loomis K. Smith B. Lipid-based nanoparticles for gene therapy. J. Control. Release 2009 144 1 22 32
    [Google Scholar]
  99. Hauss D.J. Fogal S.E. Ficorilli J.V. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 1998 87 2 164 169 10.1021/js970300n 9519148
    [Google Scholar]
  100. Kumar R. Sharma A. Goyal A. Nanostructured lipid carriers: The future of drug delivery systems. Int. J. Pharm. Sci. Res. 2012 3 11 3767 3780
    [Google Scholar]
  101. zur Mühlen A. Schwarz C. Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998 45 2 149 155 10.1016/S0939‑6411(97)00150‑1 9704911
    [Google Scholar]
  102. Hong S.S. Lee S.Y. Lee K.S. Enhanced oral bioavailability of atorvastatin by supersaturation induced by hydroxypropylmethyl cellulose. Pharm. Dev. Technol. 2006 11 4 465 472 17101517
    [Google Scholar]
  103. Choi J.Y. Kim M.J. Kim S. Formulation and in vivo evaluation of omeprazole-loaded solid lipid nanoparticles for oral delivery. J. Microencapsul. 2006 23 7 683 691
    [Google Scholar]
  104. Chen D.B. Yang T. Lu W.L. Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 2001 49 11 1444 1447 10.1248/cpb.49.1444 11724235
    [Google Scholar]
  105. Manconi M. Valenti D. Sinico C. Lai F. Loy G. Fadda A.M. Niosomes as carriers for tretinoin II. Influence of vesicular incorporation on tretinoin photostability. Int. J. Pharm. 2003 260 2 261 272 10.1016/S0378‑5173(03)00268‑0 12842345
    [Google Scholar]
  106. Göppert T.M. Müller R.H. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int. J. Pharm. 2005 302 1-2 172 186 10.1016/j.ijpharm.2005.06.025 16098695
    [Google Scholar]
  107. Choudhury H. Gorain B. Chatterjee B. Mandal U.K. Sengupta P. Tekade R.K. Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route. Curr. Pharm. Des. 2017 23 17 2504 2531 10.2174/1381612822666161201143600 27908273
    [Google Scholar]
  108. Qureshi O.S. Kim H.S. Zeb A. Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral and parenteral administration. J. Microencapsul. 2017 34 3 250 261 10.1080/02652048.2017.1337247 28557649
    [Google Scholar]
  109. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001 47 1 65 81 10.1016/S0169‑409X(00)00122‑8 11251246
    [Google Scholar]
  110. Pottoo F.H. Sharma S. Javed M.N. Lipid-based nanoformulations in the treatment of neurological disorders. Drug Metab. Rev. 2020 52 1 185 204 10.1080/03602532.2020.1726942 32116044
    [Google Scholar]
  111. Cunha S. Forbes B. Sousa Lobo J.M. Silva A.C. Improving drug delivery for Alzheimer’s disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. Int. J. Nanomedicine 2021 16 4373 4390 10.2147/IJN.S305851 34234432
    [Google Scholar]
  112. Mehnert W. Mäder K. Lipid nanoparticles: A novel drug delivery system for poorly soluble drugs. Int. J. Pharm. 2001 214 1-2 163 173
    [Google Scholar]
  113. Müller R. Petersen R. Hommoss A. Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev. 2007 59 6 522 530 10.1016/j.addr.2007.04.012 17602783
    [Google Scholar]
  114. Arifin D.Y. Lee L.Y. Wang C.H. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. Adv. Drug Deliv. Rev. 2006 58 12-13 1274 1325 10.1016/j.addr.2006.09.007 17097189
    [Google Scholar]
  115. Liu S. Pan J. Liu G. Lipid nanoparticles for ocular drug delivery: Progress and challenges. J. Nanobiotechnology 2022 20 1 1 16 34980143
    [Google Scholar]
  116. Jaiswal M Dudhe R Sharma PK Nanoemulsion: an advanced mode of drug delivery system 3 Biotech 2015 5 2 123 7 10.1007/s13205‑014‑0214‑0 28324579
    [Google Scholar]
  117. Dudhipala N Janga KY Gorre T Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: Preparation, characterization, permeation and pharma-cokinetic evaluation. Artif Cells Nanomed Biotechnol 2018 46 sup2 616 25 10.1080/21691401.2018.1465068
    [Google Scholar]
  118. Patel R.J. Patel Z.P. Formulation optimization and evaluation of nanostructured lipid carriers containing valsartan. Int J Pharm Sci Nanotechnol 2013 6 2 2077 2086 10.37285/ijpsn.2013.6.2.10
    [Google Scholar]
  119. Thapa C. Ahad A. Aqil M. Imam S.S. Sultana Y. Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design. J. Drug Deliv. Sci. Technol. 2018 44 431 439 10.1016/j.jddst.2018.02.003
    [Google Scholar]
  120. Paudel A Ameeduzzafar , Imam SS, et al. Formulation and optimization of candesartan cilexetil nano lipid carrier: In vitro and in vivo evaluation. Curr. Drug Deliv. 2017 14 7 1005 1015 28034361
    [Google Scholar]
  121. Agrawal Y.O. Patil K.D. More K.R. Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment. J. Drug Deliv. Sci. Technol. 2022 77 103894 10.1016/j.jddst.2022.103894
    [Google Scholar]
  122. Shah N.V. Seth A.K. Balaraman R. Aundhia C.J. Maheshwari R.A. Parmar G.R. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J. Adv. Res. 2016 7 3 423 434 10.1016/j.jare.2016.03.002 27222747
    [Google Scholar]
  123. Jawahar N. Hingarh P.K. Arun R. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int. J. Biol. Macromol. 2018 110 269 275 10.1016/j.ijbiomac.2018.01.121 29402457
    [Google Scholar]
  124. Shevalkar G. Vavia P. Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe. J. Drug Deliv. Sci. Technol. 2019 53 101211 10.1016/j.jddst.2019.101211
    [Google Scholar]
  125. Fathi H.A. Allam A. Elsabahy M. Fetih G. El-Badry M. Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin. Colloids Surf. B Biointerfaces 2018 162 236 245 10.1016/j.colsurfb.2017.11.064 29197789
    [Google Scholar]
  126. Kaithwas V. Dora C.P. Kushwah V. Jain S. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Colloids Surf. B Biointerfaces 2017 154 10 20 10.1016/j.colsurfb.2017.03.006 28284054
    [Google Scholar]
  127. Niu X. Wan L. Hou Z. Mesoporous carbon as a novel drug carrier of fenofibrate for enhancement of the dissolution and oral bioavailability. Int. J. Pharm. 2013 452 1-2 382 389 10.1016/j.ijpharm.2013.05.016 23688621
    [Google Scholar]
  128. Elmowafy M. Ibrahim H.M. Ahmed M.A. Shalaby K. Salama A. Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks. Drug Deliv. 2017 24 1 932 941 10.1080/10717544.2017.1337823 28617150
    [Google Scholar]
/content/journals/cnm/10.2174/0124054615364839250623094350
Loading
Nanostructured Lipid Carriers: Enhancing Delivery of Poorly Soluble Drugs
Bentham Science Publishers ; https://doi.org/10.2174/0124054615364839250623094350
/content/journals/cnm/10.2174/0124054615364839250623094350
/content/journals/cnm/10.2174/0124054615364839250623094350
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Nanostructured lipid carrier (NLC) ; formulation methods ; characterization,applications ; excipients ; poorly soluble drugs

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test